RBC Capital: 'Miebo remains the second-largest Rx DED drug in the US with 22.8% market share' Jun 5, 2026 08:49AM
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference May 13, 2026 07:00AM
RBC Capital on Bausch & Lomb Corp. (BLCO): 'We view the delay in anticipated competition in the US Rx DED market as neutral to slightly positive' Mar 17, 2026 09:36AM
Bausch & Lomb Corp. (BLCO) PT Raised to $21 at RBC Capital Jan 27, 2026 04:29AM
Bausch & Lomb Corp. (BLCO) PT Raised to $19 at RBC Capital Nov 14, 2025 04:30AM


Jul 15, 2025 09:45AM RBC Capital on Bausch & Lomb Corp. (BLCO): 'FX Likely a Tailwind'
Apr 4, 2025 08:49AM Bausch & Lomb Corp. (BLCO) PT Lowered to $17 at RBC Capital on Revised Estimates
Oct 22, 2024 06:34AM Bausch & Lomb Corp. (BLCO) PT Raised to $23 at RBC Capital
Jul 22, 2024 06:22AM Bausch & Lomb Corp. (BLCO) PT Raised to $20 at RBC Capital
Apr 22, 2024 06:23AM Bausch & Lomb Corp. (BLCO) PT Lowered to $18 at RBC Capital
Feb 15, 2023 01:33PM Bausch + Lomb (BLCO) to name new CEO; RBC Capital remains bullish ahead of 4Q print
Jul 25, 2022 04:21PM UPDATE: RBC Capital Starts Bausch & Lomb Corp. (BLCO) at Outperform
May 13, 2022 07:00AM Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference